700 related articles for article (PubMed ID: 23400082)
41. Intravitreal ranibizumab for patients with neovascular age-related macular degeneration with good baseline visual acuity.
Kato A; Yasukawa T; Suga K; Hirano Y; Nozaki M; Yoshida M; Ogura Y
Ophthalmologica; 2015; 233(1):27-34. PubMed ID: 25412682
[TBL] [Abstract][Full Text] [Related]
42. Changes of choroidal neovascularization in indocyanine green angiography after intravitreal ranibizumab injection.
Lee JE; Kim HW; Lee SJ; Lee JE
Retina; 2015 May; 35(5):999-1006. PubMed ID: 25590857
[TBL] [Abstract][Full Text] [Related]
43. Intravitreal ranibizumab for choroidal neovascularization with large submacular hemorrhage in age-related macular degeneration.
Iacono P; Parodi MB; Introini U; La Spina C; Varano M; Bandello F
Retina; 2014 Feb; 34(2):281-7. PubMed ID: 23851632
[TBL] [Abstract][Full Text] [Related]
44. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study.
Cohen SY; Mimoun G; Oubraham H; Zourdani A; Malbrel C; Queré S; Schneider V;
Retina; 2013 Mar; 33(3):474-81. PubMed ID: 23266880
[TBL] [Abstract][Full Text] [Related]
45. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
46. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
47. Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
Papavasileiou E; Steel DH; Liazos E; McHugh D; Jackson TL
Retina; 2013 Apr; 33(4):846-53. PubMed ID: 23400079
[TBL] [Abstract][Full Text] [Related]
48. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration.
Muether PS; Hermann MM; Dröge K; Kirchhof B; Fauser S
Am J Ophthalmol; 2013 Nov; 156(5):989-993.e2. PubMed ID: 23938122
[TBL] [Abstract][Full Text] [Related]
49. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany.
Finger RP; Wiedemann P; Blumhagen F; Pohl K; Holz FG
Acta Ophthalmol; 2013 Sep; 91(6):540-6. PubMed ID: 23171290
[TBL] [Abstract][Full Text] [Related]
50. Determinants of fixation in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
Mathew R; Pearce E; Sivaprasad S
Am J Ophthalmol; 2012 Mar; 153(3):490-496.e1. PubMed ID: 22071230
[TBL] [Abstract][Full Text] [Related]
51. Role of posterior vitreous detachment on outcome of anti-vascular endothelial growth factor treatment in age-related macular degeneration.
Üney GÖ; Ünlü N; Acar MA; Hazirolan D; Altiparmak UE; Yalniz-Akkaya Z; Örnek F
Retina; 2014 Jan; 34(1):32-7. PubMed ID: 23751943
[TBL] [Abstract][Full Text] [Related]
52. Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab.
Bloch SB; Lund-Andersen H; Sander B; Larsen M
Am J Ophthalmol; 2013 Jul; 156(1):116-124.e1. PubMed ID: 23664150
[TBL] [Abstract][Full Text] [Related]
53. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
[TBL] [Abstract][Full Text] [Related]
54. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab.
Wolf A; Rüping J; Neubauer AS; Mayer W; Ulbig M; Haritoglou C; Holz FG; Eter N; Kampik A
Retina; 2013 Oct; 33(9):1843-9. PubMed ID: 23598795
[TBL] [Abstract][Full Text] [Related]
55. Three-year follow-up of a pilot study of ranibizumab combined with proton beam irradiation as treatment for exudative age-related macular degeneration.
Park SS; Daftari I; Phillips T; Morse LS
Retina; 2012 May; 32(5):956-66. PubMed ID: 22183743
[TBL] [Abstract][Full Text] [Related]
56. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
58. Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison.
Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Brandão EM; Falcão-Reis F; Carneiro AM
Ophthalmologica; 2014; 232(3):149-55. PubMed ID: 25196907
[TBL] [Abstract][Full Text] [Related]
59. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
60. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
Kim JH; Chang YS; Kim JW; Kim CG; Yoo SJ; Cho HJ
Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
